Foff Erin Pennock 4

What Happened

• Erin Pennock, Chief Medical Officer of MapLight Therapeutics, sold a total of 4,438 shares in open‑market transactions on May 7, 2026, generating about $126,640 in proceeds. The bulk sale was 4,321 shares at a weighted average price of $28.52 ($123,235), plus a smaller sale of 117 shares at a weighted average price of $29.10 ($3,405). These were sales (not purchases), which are often routine dispositions rather than a bullish signal.

Key Details

• Transaction date: May 7, 2026.
• Sales:
  • 4,321 shares at a weighted avg price $28.52 (range $28.08–$29.045) — $123,235.
  • 117 shares at a weighted avg price $29.10 (range $29.09–$29.10) — $3,405.
• Total shares sold: 4,438; total proceeds ≈ $126,640.
• Shares owned after transaction: not provided in the transaction excerpt (check the full Form 4 for post‑transaction holdings).
• Footnotes:
  • Transaction executed pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025 (pre‑arranged sales).
  • Reported prices are weighted averages; detailed per‑trade price breakdowns are available on request per the footnotes.
• Filing timeliness: Form 4 filed May 11, 2026 for a May 7 transaction — appears to meet the standard 2‑business‑day filing requirement (timely).

Context

• A 10b5‑1 plan means the sales were made under a pre‑set trading arrangement, which can limit the ability to infer insider sentiment from the sale. Sales (code S) typically reflect liquidity or diversification needs rather than an operational judgment about the company. For full context, investors should review the complete Form 4 for Pennock and other recent insider transactions.